COVID-19 Summary of Evidence report updated
The COVID-19 Summary of Evidence report has been updated with information to reflect that the Omicron subvariant BA.2 is prevalent and that long-term outcomes for recipients include the possibility of thrombotic events.
Compiled by the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC), the document includes the latest information known for minimizing the risk of donor-derived COVID-19 transmission while maximizing donor utilization.
The committee developed the summary in collaboration with colleagues representing AST, ASTS, AOPO, HRSA and the CDC. DTAC is reviewing the document on a quarterly basis.
FDA approves first COVID-19 treatment for young children
The U.S. Food and Drug Administration (FDA) has expanded the approval of Veklury (remdesivir) to include pediatric patients 28 days of age or older who weigh at least 3 kilograms and who are hospitalized or at high risk for progression to severe COVID-19. Read the full release.
FDA authorizes COVID-19 diagnostic test using breath samples
The new test detects chemicals compounds in breath samples associated with a SARS-CoV-2 infection. Read the full release from the FDA.
Distribution of sotrovimab paused nationwide
- The National Institute of Health’s (NIH) COVID-19 Treatment Guidelines Panel no longer recommends sotrovimab as a treatment option for non-hospitalized patients, citing substantially decreased in vitro activity against the dominant COVID-19 subvariant Omicron BA.2. Read the latest recommendations from NIH.
Help your patients locate Evusheld therapy
- The U.S. Department of Health and Human Services maintains a national map displaying public locations that have received shipments of COVID-19 therapeutics such as Evusheld, Molnupiravir and Bebtelovimab. These therapies require a prescription, and the locator is intended for provider use.
The latest data on organ donation and transplant in the U.S.
- Find high-level data on transplants, deceased donors recovered, patients added to the waitlist and patients temporarily moved to inactive waitlist status.